Advancements in the treatment of mycosis fungoides and Sezary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.

ABSTRACT: Mycosis fungoides (MF) and Sézary syndrome (SS) are forms of cutaneous T cell lymphoma (CTCL) that pose significant challenges in their clinical management, particularly in refractory and advanced-stage disease. With the emergence of novel therapeutic modalities however, there are increasing opportunities to exploit the current understanding of pathophysiologic mechanisms of MF/SS for treatment. This review summarizes recent advances in the treatment of MF/SS, with a focus on monoclonal antibodies, immunotherapies, and Janus kinase (JAK) inhibitors, including ongoing clinical trials.

SUBMITTER: Quadri I 

PROVIDER: S-EPMC10654973 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature